OcTMAB for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 24 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

OcTMAB may be beneficial for COVID-19 according to the study below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 11,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed OcTMAB in detail.

Study suggesting benefit with OcTMAB

Song et al., SARS-CoV-2 pseudoparticles preferentially infect ectoderm in human embryonic tissues, Frontiers in Cell and Developmental Biology, doi:10.3389/fcell.2026.1733662

Introduction The early stages of human embryonic development are challenging to study in pregnant women. Methods A “disease-in-a-dish” model was utilized to investigate SARS-CoV-2 infection of human embryonic stem cells and the three germ layers (ectoderm, endoderm, and mesoderm). Results Ectodermal cells showed significantly higher infection rates compared to the other cell types. This increased susceptibility was attributed to three key factors characteristic of the ectoderm: dual viral entry pathways (membrane fusion and endocytosis), elevated TMPRSS2 activity, and a markedly reduced glycocalyx, which facilitated viral access to host cell receptors. Discussion Our findings provide strong evidence that cells in early post-implantation human embryos are susceptible to SARS-CoV-2 infection. The high level of infection in the ectodermal cells raises concern for potential teratogenic effects, particularly involving the nervous system. Future clinical studies should investigate neurological outcomes in infants born to mothers infected with SARS-CoV-2 during pregnancy.